-
公开(公告)号：US20220002236A1
公开(公告)日：2022-01-06
申请号：US16768866
申请日：2018-11-19
Inventor： Ji Hoon PARK , Tae Sun CHANG , Young Woo YOU , lljeong HEO , Jin Hee LEE , Seul Gi HAN , Kwan Yong JEONG
IPC: C07C269/04 , B01J23/10 , B01J23/44
Abstract: The present invention relates to a method of directly preparing a dicarbamate compound from a diamine compound, and more particularly to a method of directly preparing a dicarbamate compound by reacting a diamine compound with an alcohol compound in the presence of a mixed gas of carbon monoxide (CO) and oxygen (O2) using a Pd/MOx catalyst configured such that a palladium (Pd) active metal is supported on a metal oxide or metalloid oxide carrier.
-
公开(公告)号：US20210395695A1
公开(公告)日：2021-12-23
申请号：US17283942
申请日：2019-12-20
Inventor： Eun-Mi Kim , Ki-Suk Kim , Hyang-Ae Lee
IPC: C12N5/071 , C12M3/00 , C12N5/0786
Abstract: The present invention relates to a method for fabrication of a three-dimensional lung organoid comprising human stem cell-derived alveolar macrophages. Specifically, a lung organoid is fabricated by co-culturing cells not expressing the definitive endoderm marker CRCX4 according to a fabrication method of the present disclosure. The lung organoid comprises type 1 and type 2 alveolar epithelial cells as well as alveolar macrophages and realizes infectious or inflammatory responses unlike conventional lung organoids that contain no immune cells and as such, can be advantageously used in studying mechanisms of related lung diseases, excavating biomarkers, developing therapeutic agents, and so on.
-
43.发明申请公开(公告)号：US20210354113A1
公开(公告)日：2021-11-18
申请号：US17281114
申请日：2019-05-14
Inventor： Yong Ki PARK , Won Choon CHOI , Daesung PARK , Hawon PARK , Changyeol SONG , Deuk Soo PARK , Ung Gi HONG , Miyoung LEE
Abstract: Disclosed is a catalyst for producing an olefin including an oxygen carrier material and a dehydrogenation catalyst. The catalyst allows hydrogen to be converted into water by using oxygen inside the lattice of an oxide catalyst without the additional supply of oxygen, and thus, the conversion can be increased while the decrease in selectivity, which is a disadvantage of an additional oxidative dehydrogenation reaction (ODHP), is suppressed.
-
公开(公告)号：US11166891B2
公开(公告)日：2021-11-09
申请号：US16562298
申请日：2019-09-05
Inventor： Woo-Keun Kim , Sangwoo Lee , Seokjoo Yoon , Chul Min Park
IPC: C07C43/215 , A61K8/33 , C07C43/285 , C07C41/30 , A23L33/10 , A61Q19/02
Abstract: The present invention relates to a bis phenyl hexa triene derivative, a preparation method thereof and a composition for skin whitening comprising the same as an active ingredient. The said derivative inhibits the expression of tyrosinase, TRP 1 (tyrosinase-related protein 1), TRP 2 (tyrosinase-related protein 2) or MITF (microphthalmia-associated transcription factor) gene which produces a precursor necessary for the generation of melanin, suppresses the activity of tyrosinase, eventually inhibits the biosynthesis of melanin, is safe due to low cytotoxicity, and has less side effects and excellent antioxidative effect, so that it can be effectively used as a composition for skin whitening.
-
公开(公告)号：US20210332029A1
公开(公告)日：2021-10-28
申请号：US17268869
申请日：2019-08-12
Inventor： Kwangho Lee , Gildon Choi , Seoyoung Lee , Jiwon Kim , Byoung Chul Cho , Chae Won Park , Jiyeon Yun
IPC: C07D403/06 , C07D471/04 , C07D403/14 , C07D401/14 , A61K45/06
Abstract: The present invention relates to an isoindolin-1-on derivative, a method for preparing same, and a pharmaceutical composition comprising same as an effective component for preventing or treating tumors, wherein the isoindolin-1-on derivative exhibits a high inhibitory effect on EGFR mutations, and thus can be beneficially used for the treatment of EGFR-mutated tumors, and the isoindolin-1-on derivative exhibits a significant synergistic effect when co-administered, and thus can be beneficially used in concomitant therapy.
-
Patent Agency Ranking
公开(公告)号：US20210322362A1
公开(公告)日：2021-10-21
申请号：US17235140
申请日：2021-04-20
Applicant: Novartis AG , Katholieke Universiteit Leuven , Korea Research Institute of Chemical Technology
Inventor： Johan NEYTS , Daniel POON , Keith Bruce PFISTER
IPC: A61K31/343 , C07D307/93 , A61P31/14
Abstract: This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.
-
公开(公告)号：US11147807B2
公开(公告)日：2021-10-19
申请号：US16603993
申请日：2018-02-28
Applicant: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY , KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
Inventor： Seong Eon Ryu , Tae Hyun Park , Kwang Hwan Lee , Ju Seop Kang , Shin Hee Kim , Kyoung Tae Nam , Hyeon Kyu Lee
Abstract: The present invention relates to a pharmaceutical composition comprising a DUSP1 inhibitor. The pharmaceutical composition comprising the DUSP1 inhibitor according to the present invention can solve the problems of inhibitors that target the active site because it inhibits DUSP1 by an allosteric inhibitory mechanism, and is effective for preventing or treating diseases involving DUSP1 enzymes, for example, a cancer such as a liver cancer, a breast cancer and a pancreatic cancer, a hepatitis C, and a depression. In particular, the DUSP1 inhibitor according to the present invention is very effective in treating a depression because it directly acts on neuronal growth.
-
公开(公告)号：US20210253544A1
公开(公告)日：2021-08-19
申请号：US17271354
申请日：2019-08-29
Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION , KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , NATIONAL CANCER CENTER
Inventor： Bong-Jin LEE , Kyu-Yeon LEE , Sang Jae LEE , Dong-Gyun KIM , Joo Youn LEE , Kwan-Young JEONG , Heui Cherl YANG , Hyeon-Kyu LEE , Hyoun Sook KIM
IPC: C07D277/32 , A61P35/00 , A61P3/06
Abstract: A nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like (NSDHL) inhibitor provided according to an aspect of the present invention can be used not only as an anticancer agent capable of overcoming resistance to EGFR-targeting anticancer agents, but also advantageously in the treatment of hyperlipidemia.
-
公开(公告)号：US20210231539A1
公开(公告)日：2021-07-29
申请号：US17051126
申请日：2019-02-14
Inventor： SunHyun PARK , Ki-Suk KIM
IPC: G01N1/30 , G01N33/68 , G01N33/532
Abstract: The present invention relates to a composition for immunostaining cleared large tissues and a method for immunostaining cleared large biological tissues using the same. The composition for immunostaining cleared large tissues increases antibody permeability in cleared biological tissues, in particular, large biological tissues having a thickness of 3 mm or more, to allow antibodies to penetrate deep into thick tissues, thereby overcoming immunostaining problems associated with limited permeation of antibodies in existing methods, reduces the time required for immunostaining large tissues, thereby enabling simple and rapid three-dimensional bioimaging with high resolution for large biological tissues, and may be beneficially used, through structure images, for identifying the causes of various diseases, developing new treatment methods, and predicting the efficacy and toxicity of drugs. Furthermore, the composition for immunostaining cleared large tissues may be used in combination with various medical devices, and in particular, may be prepared as a kit and beneficially used as an in vitro diagnostic device.
-
公开(公告)号：US11053520B2
公开(公告)日：2021-07-06
申请号：US16548093
申请日：2019-08-22
Inventor： Jeong Chan Joo , Hee Taek Kim , Bong Keun Song , Kyoung Hee Kang , Tae Uk Kang , Si Jae Park
Abstract: The present disclosure pertains to a recombinant Corynebacterium glutamicum strain for production of glutaric acid and a method for production of glutaric acid by using the same. When used to produce glutaric acid, the recombinant Corynebacterium glutamicum strain guarantees an excellent output and allows the selective production of glutaric acid without generation of byproducts, which needs no isolation and purification processes and thus leads to an economical benefit. Consequently, the recombinant strain is useful for production of glutaric acid.
-
-
-
-
-
-
-
-
-
Search Results
640
records
(took 0.026 seconds)
